API | pf-00610355

pf-00610355 Report issue

Small molecule Experimental

AACT DrugBank MeSH PubChem

Active Ingredient History

NOW

Chemistry

SMILES: CC(C)(Cc1cccc(CC(=O)NCc2cccc(-c3ccc(O)cc3)c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1
InChIKey: YPHDIMUXXABSSO-YTTGMZPUSA-N
Mol. Mass: 617.77
ALogP: 4.64 Partition coefficient
ChEMBL Molecule:
pf-00610355

More Chemistry

Pharmacology

Mechanisms of Action:
- Beta-2 adrenergic receptor (Canis lupus familiaris) ^UniProt
- Beta-2 adrenergic receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

n-((4'-hydroxybiphenyl-3-yl)methyl)-2-(3-(2-((-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-2-methylpropyl)phenyl)acetamide | pf-00610355 | pf610355 | pf 610355 | pf-610355

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Asthma (Phase 2)

Bronchial Diseases (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Moxifloxacin (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Respiratory Tract Diseases (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue